Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Schering AG and Biogen Idec have begun trials with the anticancer drug Zevalin, developed to treat non-Hodgkin's lymphoma.
Subscribe to our email newsletter
The study will evaluate the efficacy and safety of Zevalin in patients with diffuse large-B-cell lymphoma (DLBCL) the most common type of aggressive non-Hodgkin's lymphoma.
The primary endpoint for the trial is overall survival (OS), with disease-free survival and health-related quality of life as secondary endpoints. Once the final data from the trial are completed and analyzed, Schering AG and Biogen Idec expect to file an application seeking to expand the product's current label to include first-line therapy for patients with aggressive DLBCL.
“Diffuse large-B-cell lymphoma is a disease that progresses very fast. It's important that patients have options that provide the best efficacy available, especially in this indication where a complete cure is the goal,” said Peter Zundorf, head of Schering Group's oncology global business unit.
The total duration of the trial is anticipated to be about four years.